Loading…
for educational and safety purposes
Sermorelin and Tesamorelin both come up in the same conversations; they overlap on Growth Hormone. Sermorelin: Sermorelin is a synthetic analogue comprising the first 29 amino acids of growth hormone-releasing hormone (GHRH), the shortest fragment that retains full biological activity at the pituitary GHRH receptor. Tesamorelin: Tesamorelin is a synthetic analog of growth hormone-releasing hormone and the first therapy approved by the FDA specifically to reduce excess visceral abdominal fat, in HIV-associated lipodystrophy.
Sermorelin is a synthetic analogue comprising the first 29 amino acids of growth hormone-releasing hormone (GHRH), the shortest fragment that retains full biological activity at the pituitary GHRH receptor. Rather than supplying growth hormone directly, it stimulates the somatotrophs to secrete the body's own hormone, preserving the natural pulsatile rhythm and leaving intact the negative feedback that guards against overexposure. Once approved for the diagnosis and treatment of growth hormone deficiency, it is now used chiefly in compounding and research settings, where interest centers on recovery, body composition, and sleep. The broader GHRH-receptor family it belongs to is under active study for effects well beyond the pituitary, including agonist protection in heart failure and antagonist activity against prostatic hyperplasia, fibrosis, and tumor growth.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone and the first therapy approved by the FDA specifically to reduce excess visceral abdominal fat, in HIV-associated lipodystrophy. By stimulating the body's own pulsatile release of growth hormone it lowers deep abdominal fat and raises IGF-1; beyond that, trials have shown it reduces liver fat in fatty liver disease and, by restoring more youthful pulsatile GH signaling, has improved muscle mitochondrial function and measures of cognition. It is marketed as Egrifta and given by daily injection.
both fingerprints on one instrument; where the marks line up the two compounds work the same lever, where a slot goes dark only one of them touches it. read straight from each entry's affinity table; nothing here is invented.
Agonist prompting GH synthesis and release
Indirect rise via increased GH
Reinforces the nighttime GH pulse
agonist
raises
reduces
strengths are the entries' qualitative ratings (strong / moderate / weak); Ki and EC50 figures appear where an entry records them.
easiest to source: Tesamorelin is currently listed by more trusted vendors (6), so it's the simpler one to get hold of. for effects and safety, read each full entry; this is educational, not medical advice.